Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis

Acta Neurologica Scandinavica

Volumn 106, Issue 1, 2002, Pages 39-43

  Niebroj Dobosz, I ^a,b   Janik, P ^a   Kwiecinski H ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Amino acids; Amyotrophic lateral sclerosis; Riluzole; Serum

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; RILUZOLE;

ADULT; AGED; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NERVE DEGENERATION; NERVOUS TISSUE; NEUROTRANSMISSION; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AMINO ACIDS; AMYOTROPHIC LATERAL SCLEROSIS; ASPARTIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCINE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; REFERENCE VALUES; RILUZOLE; TIME;

EID: 0036085274     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2002.00206.x     Document Type: Article

References (36)

1. Excitotoxic neuronal death in amyotrophic lateral sclerosis
2. Glutamate, excitotoxicity and amyotrophic lateral sclerosis
3. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
4. Branched-chain amino acids and amyotrophic lateral sclerosis
5. A pilot of dextromethorphan in amyotrophic lateral sclerosis
6. Antiglutamate therapy in amyotrophic lateral sclerosis: A trial with Lamotrigine
7. A controlled trial of Riluzole in amyotrophic lateral sclerosis
8. Riluzole and ALS therapy
9. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
10. Management of amyotrophic lateral sclerosis with riluzole
11. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with Riluzole
12. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
13. Determination of transmitter- and non-transmitter-related amino acids in human samples by high performance liquid chromatography
14. High performance liquid chromatographic determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phthalaldehyde
15. Electrochemical activity of o-phthalaldehyde mercaptoethanol derivatives of amino acids: Application to high-performance liquid chromatographic determination of amino acids in plasma and other biological materials
16. Fluorescence reaction for amino acids
17. Free amino acid levels in amyotrophic lateral sclerosis
18. Elevated levels of amino acids in the CSF of motor neuron disease patients
19. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: Subtype analysis
20. Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS)
21. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetylaspartyl-glutamate in amyotrophic lateral sclerosis
22. Excitatory amino acids in amyotrophic lateral sclerosis: An update
23. CSF plasma amino acid level in motor neuron disease: Elevation of CSF glutamate in a subset of patients
24. 2-Amino-6-trifluoromethoxybenzothiazole, a possible antagonist of excitatory amino acid neurotransmission - I. Anticonvulsant properties
25. The neuroprotective agent riluzole inhibits release of L-glutamate and L-aspartate from slices of hippocampal are CA1
26. Riluzole inhibits the release of glutamate in the caudate nucleus in the cat in vivo
27. Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells
28. The pharmacology and mechanism of action of riluzole
29. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed by Xenopus oocytes
30. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes
31. Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism
32. Glutamate transporters are oxidant-vulnerable: A molecular link between oxidative and excitotoxic neurodegeneration?
33. Neuroprotective effects of riluzole in ALS CSF toxicity
34. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis
35. Riluzole: A new agent for amyotrophic lateral sclerosis
36. The Riluzole early access programme: Descriptive analysis of 844 patients in France